Plasma protein-binding ligands

Details Plasma protein-binding ligands Plasma protein-binding ligands

2007-05-29

2007-05-29

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C530S300000, C530S329000

Reexamination Certificate

active

10414524

ABSTRACT:
The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence selected from specific amino acid sequences provided herein. Alternatively, the isolated or purified protein binds to αl proteinase inhibitor and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase. The peptide comprises no more than 10 amino acids and comprises an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3, and amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2, or an amino acid sequence selected from specific amino acid sequences provided herein. In addition, the invention provides isolated or purified peptide that binds to von Willebrand Factor. The peptide comprises an amino acid sequence Xaa4-Xaa5-Xaa5, an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, or an amino acid sequence selected from specific amino acid sequences provided herein.

REFERENCES:
patent: 5010175 (1991-04-01), Rutter et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5235039 (1993-08-01), Heath, Jr. et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5723579 (1998-03-01), Buettner et al.
patent: 5780090 (1998-07-01), Frerot et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 5994309 (1999-11-01), Mazar et al.
patent: 6004757 (1999-12-01), Cantley et al.
patent: 6207397 (2001-03-01), Lynch et al.
patent: 6696416 (2004-02-01), Mazar et al.
patent: 0 679 658 (1995-11-01), None
patent: WO 92/00091 (1992-01-01), None
patent: 00/43490 (2000-07-01), None
patent: WO 01/31019 (2001-05-01), None
patent: WO 03/016904 (2003-02-01), None
Aviram et al., “Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves its Free Sulfhydryl Group and is Different from that Required for its Arylesterase/Paraoxonase Activities,”Arterioscler. Thromb. Vasc. Biol., 18(10): 1617-24 (1998).
Baumbach et al., “Protein Purification Using Affinity Ligands Deduced from Peptide Libraries,”BioPharm., May 24-31, 1992.
Costa et al., “Functional Genomics of the Praoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug Metabolism,”Ann. Rev. Med., 54(37): 371-392 (2003).
Federici et al., “Diagnosis of von Willebrand Disease,”Haemophilia, 4: 654-660 (1998).
Furka et al., “General Method for Rapid Synthesis of Multicomponent Peptide Mixtures,”Int. J. Peptide Protein Res., 37: 487-493 (1991).
Ginsburg, “Molecular Genetics of von Willebrand Disease,”Thrombosis and Haemostasis, 82(2): 585-591 (1999).
Hackeng et al., “Low-density Lipoprotein Enhances Platelet Secretion Via Integrin-alpha11bbeta3-Mediated Signaling,”Arteriosclerosis Thromb. Vasc. Biol., 19(2): 239-247 (1999).
Johnson et al., “human Alpha-1-Proteinase Inhibitor Mechanism of Action: Evidence for Activation by Limited Proteolysis,”Biochem. Biophys. Res. Comm., 72: 33-39 (1976).
Katz et al., “Surface Reconsitution of a de novo Synthesized Hemoprotein for Bioelectronic Applications,”Angew. Chem. Int. Ed., 37(23): 3253-3256 (1998).
Lam et al., “A New Type of Synthetic Peptide Library for Identifying Ligand-binding Activity,”Nature, 354(6348): 82-84 (1991).
Mackness et al., “Effect of the Human Serum Paraoxonase 55 and 192 Genetic Polymorphisms on the Protection by High Density Lipoprotein Against Low Density Lipoprotein Oxidative Modification,”FEBS Lett., 423(1): 57-60 (1998).
Racusen et al., “Microscale, Filtration-Type Binding Assay for Studying Myosin-Erythrocyte Protein 4.1 Interactions,”Analytical Biochemistry, 188: 344-348 (1990).
Rodeghiero et al., “Epidemiological Investigation of the Prevalence of von Willebrand's Disease,”Blood, 69: 454-459 (1987).
Ruggeri et al., “von Willebrand Factor,”FASEB J., 7(2): 308-316 (1993).
Sadler et al., “von Willebrand Factor,”Journal of Biological Chemistry, 266(34): 22777-2278 (1991).
Sugg et al., “Cyclic Lactam Analogues of Ac-[Nle4]alpha-MSH4-11-NH2,”Biochemistry, 27(21): 8181-8188 (1988).
Turck, “Radioactive Screening of Synthetic Peptide Libraries,”Companion to Methods in Enzymology, 6(4): 396-400 (1994).
Werner et al., “prevalene of von Willebrand Disease in Children: A Multiethnic Study,”J. Pediatr., 123: 893-898 (1993).
Patrick G. Swann et al., “Nonspecific Protease-Catalyzed Hydrolysis/Synthesis of a Mixture of Peptides: Product Diversity & Ligand Amplification by a Molecular Trap”, BIOPOLYMERS, vol. 40, No. 6, pp. 617-625 (1996).
C. Kuyas et al., “Isolation of Human Fibrinogen and its Derivatives by Affinity Chromatography on Gly-Pro-Arg-Pro-Lys-Fractogel”, Thrombosis & Haemostasis, 63 (3), 1990, pp. 439-444.
Deborah B. Kaufman et al., “Affinity Purification of Fibrinogen Using a Ligand from a Peptide Library”, Biotechology & Bioengineering, vol. 77, No. 3, pp. 278-289, Feb. 5, 2002.
K. Mondorf et al., “Screening of combinational peptide libraries: Identification of ligands for affinity purification of proteins using a radiological approach”, J. Peptide Res. 52, 1998, pp. 526-536.
Jean Cohen et al., “Cloning of Bovine Rotavirus (RF Strain): Nucleotide Sequence of the Gene Coding for the Major Capsid Protein”, VIROLOGY 138, 178-182 (1984).
E. Kohli et al., “Epitope Mapping of the Major Inner Capsid Protein of Group A Rotavirus Using Peptide Synthesis”, Virology, 194, 110-116 (1993).
Burnouf, Thierry et al., “Affinity Chromatography in the Industrial Purification of Plasma Proteins for Therapeutic Use,” J. Biochem. Biophys. Methods, vol. 49, pp. 575-586 (2001).
Huang, Ping Y. et al., “Affinity Purification of von Willebrand Factor Using Ligands Derived from Peptide Libraries,” Bioorganic & Medicinal Chemistry, vol. 4, No. 5, pp. 699-708 (1996).
Jones, C. Michael et al., “Synthetic Macrophage Activating Peptides Derived from the N-Terminus of Human MCF1,” Biochemical and Biophysical Research Communications, vol. 199, No. 1, pp. 20-25 (1994).
O'Brien, Timothy et al., “Separation of High-density Lipoproteins into Apolipoprotein E-poor and Apolipoprotein E-rich Subfractions by Fast Protein Liquid Chromatography Using a Heparin Affinity Column,” Journal of Chromatography, vol. 613, pp. 239-246 (1993).
Raper, Jayne et al., “Characterization of a Novel Trypanosome Lytic Factor from Human Serum,” Infection and Immunity, vol. 67, No. 4, pp. 1910-1916 (1999).
Rich, Daniel H. et al., “Synthesis of Peptide Analogues of Prothrombin Precursor Sequence 5-9. Substrate Specificity of Vitamin K Dependent Carboxylase,” J. Med. Chem., vol. 24, pp. 706-711 (1981).
Rioli, Vanessa et al., “Novel Natural Peptide Substrates for Endopeptidase 24.15, Neurolysin, and Angiotensin-converting Enzyme,” The Journal of Biological Chemistry, vol. 278, No. 10, pp. 8547-8555 (2003).

Affiliated with

Also associated with

Rating

Plasma protein-binding ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Plasma protein-binding ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasma protein-binding ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3796100